Literature DB >> 3686679

Chest x-ray survey in breast cancer follow-up--a contrary view.

C Andreoli1, F Buranelli, T Campa, A Costa, A Magni, M Pizzichetta, S Ciatto.   

Abstract

The authors report on 83 cases of intrathoracic metastases (ITM) observed as isolated first recurrences in a ten-year experience of periodic chest x-ray (CXR) survey of primary breast cancer. In 44 of 83 cases ITM were detected on CXR in absence of subjective symptoms or clinical signs (A) whereas 39 ITM cases were detected as subjectively (S) symptomatic in the interval between two planned CXR controls. Diagnosis was anticipated by CXR survey as the disease-free interval was significantly shorter (30 vs. 43 months, p less than 0.04) for A respect to S cases. Nevertheless such a diagnostic anticipation had no prognostic impact as the ten year survival from primary treatment did not differ (0.12 vs. 0.16, p = 0.6) between A and S cases. Multivariate analysis confirmed that no impact on survival from primary treatment is expected whether ITM are detected in an earlier (asymptomatic, preclinical) or in a more advanced (subjectively symptomatic) phase. CXR survey after primary treatment of breast cancer seems thus a very questionable policy.

Entities:  

Mesh:

Year:  1987        PMID: 3686679     DOI: 10.1177/030089168707300506

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  3 in total

1.  Value of bone scanning in the follow-up of breast cancer patients. A study of 1000 cases.

Authors:  H Schünemann; P J Langecker; W Ellgas; A Leonhardt; H Merkl
Journal:  J Cancer Res Clin Oncol       Date:  1990       Impact factor: 4.553

2.  Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study.

Authors:  A Nicolini; L Anselmi; C Michelassi; A Carpi
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Chest X-ray survey in the follow-up of breast cancer patients.

Authors:  S Ciatto; P Pacini; C Andreoli; S Cecchini; A Iossa; G Grazzini; F Buranelli; T Campa; A Costa; A Magni
Journal:  Br J Cancer       Date:  1989-07       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.